Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients

Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed to define the specific threshold of PAZ trough concentration (C(min)) associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Minot-This, Marie-Sophie, Boudou-Rouquette, Pascaline, Jouinot, Anne, de Percin, Sixtine, Balakirouchenane, David, Khoudour, Nihel, Tlemsani, Camille, Chauvin, Jonathan, Thomas-Schoemann, Audrey, Goldwasser, François, Blanchet, Benoit, Alexandre, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231369/
https://www.ncbi.nlm.nih.gov/pubmed/35745797
http://dx.doi.org/10.3390/pharmaceutics14061224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231369/
https://www.ncbi.nlm.nih.gov/pubmed/35745797
http://dx.doi.org/10.3390/pharmaceutics14061224

Ejemplares similares